Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors

BACKGROUND: Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed. METHODS: Here, we compared BCG antitumoral efficacy with another live attenuat...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreo, Eduardo, Uranga, Santiago, Picó, Ana, Gómez, Ana Belén, Nardelli-Haefliger, Denise, del Fresno, Carlos, Murillo, Ingrid, Puentes, Eugenia, Rodríguez, Esteban, Vales-Gómez, Mar, Pardo, Julian, Sancho, David, Martín, Carlos, Aguilo, Nacho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252205/
https://www.ncbi.nlm.nih.gov/pubmed/35781395
http://dx.doi.org/10.1136/jitc-2021-004325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252205/
https://www.ncbi.nlm.nih.gov/pubmed/35781395
http://dx.doi.org/10.1136/jitc-2021-004325

Ejemplares similares